MYR Pharmaceuticals is focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis B and D virus infections. MYR’s lead compound Bulevirtide (formerly known as Myrcludex B), a first-in-class entry inhibitor for the treatment of chronic hepatitis B and D infections, is in a phase III clinical study for the indication of chronic HDV infection. The technology was originally developed by Prof. Dr. Stephan Urban of the University of Heidelberg (Germany) and by Prof. Dr. Phillipe Gripon of INSERM (France) and represents one the most clinically advanced novel approaches for the treatment of hepatitis B and D. MYR Pharmaceuticals is headquartered in Bad Homburg (Germany). The company started its operations in 2011 and is supported by venture capital investors such as the HighTech-Gründerfonds and Maxwell Biotech Venture Fund as well as various business angels.

Biotechnology

MYR Pharmaceuticals

Dmitry Popov

Thomas Christély

Florian Vogel

Norbert Dinauer

MYR Pharmaceuticals' Leadership Team includes Dmitry Popov and 3 others.

Leadership Team

About

Team members

Other teams at MYR Pharmaceuticals

CEO and Executive Team